News and Stories

HBHI invited a panel of three guests to discuss this issue: Katey Bey, Global Head, Total Rewards, Sedgwick; Gregory Daniel, PhD, MPH, Vice President & Head of Global Public Policy, Eli Lilly and Company; and Shantanu Nundy, MD, EVP Care Delivery and Chief Health Officer, Accolade.

Dr. Suchi Saria a healthcare AI expert, was highlighted in a conversation with Drs. Tinglong Dai and Risa Wolf, emphasizing the importance of interdisciplinary collaboration, patient-centered care, and continuous learning.

2024 Annual Health Econometrics Workshop

Michelle Nguyen was part of the 2023 HBHI Graduate Institute cohort. .

Erin Connolly was part of the 2022 inaugural HBHI Graduate Institute cohort.

Arjun (Raj) Manrai, Ph.D., Assistant Professor of Biomedical Informatics, Harvard Medical School, Deputy Editor, NEJM AI

Comparison of prior authorization across insurers: cross-sectional evidence from Medicare Advantage

Dr. Xiaoxi Yao is a Health Services Research Professor and Endowed Scientific Director of Pragmatic Trials and Evaluation at Mayo Clinic's Kern Center.

The application of psychedelic therapy for a range of mental and physical health issues is emerging as a transformative treatment method but federal policy has not kept pace with the industry’s rapid development. To understand the burgeoning business landscape surrounding this innovative therapy, the Hopkins Business of Health Initiative, in partnership with the Center for Mental Health and Addiction Policy, recently convened a panel of national experts to discuss the cutting-edge convergence of psychedelics, business, and policy.  

"Happy to become a new member of @MHCCMD Payment Model Work Group" Read more on her announcement here.